Lexaria Bioscience Operating Income Over Time
| LEXX Stock | USD 0.70 0.02 2.78% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lexaria Bioscience Performance and Lexaria Bioscience Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexaria Bioscience. Expected growth trajectory for Lexaria significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Lexaria Bioscience assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.57) | Revenue Per Share | Quarterly Revenue Growth 1.071 | Return On Assets | Return On Equity |
The market value of Lexaria Bioscience Corp is measured differently than its book value, which is the value of Lexaria that is recorded on the company's balance sheet. Investors also form their own opinion of Lexaria Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Lexaria Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexaria Bioscience's market value can be influenced by many factors that don't directly affect Lexaria Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lexaria Bioscience's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lexaria Bioscience represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lexaria Bioscience's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Lexaria Bioscience Corp and related stocks such as Hoth Therapeutics, Allarity Therapeutics, and Lixte Biotechnology Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HOTH | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (2.5 M) | (7.7 M) | (7.3 M) | (14.1 M) | (11.1 M) | (7.7 M) | (8.2 M) | (7.4 M) | (7.8 M) |
| ALLR | (81.2 K) | (81.2 K) | (81.2 K) | (81.2 K) | (68.7 K) | (1.4 M) | (4.5 M) | (3.8 M) | (5 M) | (17.6 M) | (8.3 M) | (26.6 M) | (34.5 M) | (17.1 M) | (27.2 M) | (24.5 M) | (23.3 M) |
| LIXT | (32.9 K) | (1.9 M) | (2.1 M) | (1.4 M) | (2.4 M) | (2.6 M) | (2.1 M) | (1.8 M) | (2.1 M) | (2.5 M) | (3.3 M) | (6.7 M) | (6.3 M) | (5.1 M) | (3.6 M) | (3.2 M) | (3.4 M) |
| CING | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (7.1 M) | (20.7 M) | (17.5 M) | (22.8 M) | (15.6 M) | (14.1 M) | (14.8 M) |
| BCTX | (8.6 K) | (559.6 K) | (290.1 K) | (476.5 K) | (1.9 M) | (2.2 M) | (3.2 M) | (5 M) | (6.3 M) | (4.8 M) | (8.9 M) | (19.4 M) | (31.3 M) | (45.5 M) | (37.7 M) | (34 M) | (32.3 M) |
| CASI | (20 K) | (4.6 M) | 4.5 M | 5.7 M | 26.2 M | 7.2 M | 9.4 M | (10.8 M) | (26.5 M) | (40 M) | (52.8 M) | (41.5 M) | (26.5 M) | (25.1 M) | (39.6 M) | (35.7 M) | (33.9 M) |
| PCSA | (160 K) | (770 K) | (2.3 M) | (3 M) | (4.2 M) | (987.2 K) | 2.7 M | (1.8 M) | (4.5 M) | (3.9 M) | (15.1 M) | (12.1 M) | (27.5 M) | (11.5 M) | (12.1 M) | (10.8 M) | (10.3 M) |
| CRIS | (13.9 M) | (7.2 M) | (18.6 M) | (9.4 M) | (15.9 M) | (56.5 M) | (58 M) | (49.8 M) | (29.3 M) | (24.4 M) | (24.9 M) | (42.1 M) | (53 M) | (48.3 M) | (44.5 M) | (40.1 M) | (42.1 M) |
Lexaria Bioscience Corp and related stocks such as Hoth Therapeutics, Allarity Therapeutics, and Lixte Biotechnology Operating Income description
Operating Income is the amount of profit realized from Lexaria Bioscience Corp operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Lexaria Bioscience Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Lexaria Bioscience Corp | LEXX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 740 McCurdy Road, |
| Exchange | NASDAQ Exchange |
USD 0.7
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.